29th EWMA Conference: Latest Clinical Data on Nexodyn® AOS Demonstrating Higher Healing Performance in Chronic Leg Ulcers Presented by Applied Pharma Research

Balerna, Switzerland (ots/PRNewswire) - APR Applied Pharma
Research sa (APR) presented at the recent 29th conference of the
European Wound Management Association (EWMA) in Göteborg, the results
of a clinical study confirming Nexodyn® AcidOxidizing Solution (AOS)
to promote the restart of the healing process in chronic leg ulcers.

Conducted by Prof. R Strohal and colleagues, this non-inferiority
clinical study aimed at comparing wound healing performance and
safety profile of Nexodyn® AOS vs standard of care in the treatment
of chronically-colonized or infected leg ulcers.

A total of 50 patients, presenting chronic ulcers with
unsatisfactory healing in the 6 weeks before study enrollment, were
randomized into 2 groups of 25 each - one group treated with standard
of care (modern dressings plus antiseptic if needed), while the other
group treated with Nexodyn® AOS in association with low-cost
dressings, and followed up for at least 6 weeks.

Overall Nexodyn® AOS has proven to be able to restart wound
healing significantly better than standard of care while showing a
more favorable safety profile.

In particular, compared to baseline the treatment with Nexodyn®
AOS has been associated with significantly higher complete healing
(32% vs 8%; p=0.034), higher relative wound size reduction (81.54% vs
44.68%; p<0.0001), faster wound size reduction (p=0.0076) and steeper
wound pH reduction (p<0.0001). The study also evaluated the safety
and tolerability of the treatment including Nexodyn® AOS, showing a
more encouraging safety profile with less adverse events reported and
no severe adverse events vs standard of care.

These remarkable data were divulged at the recent EWMA conference
by Prof. Strohal, during a lecture where an international audience
had the opportunity to learn about the role that the utilization of
Nexodyn® AOS could play in the wound bed preparation routine to
restart wound healing in stalled wounds.

"We are very proud of these results which reinforce Nexodyn® AOS
efficacy and safety profile as a wound healing restarter in chronic
wounds. Actually, restarting healing in stalled wounds is a priority
both from patients' and HCPs' perspective on a global basis: we are
confident that Nexodyn® AOS could make the difference as it creates
the ideal microenvironment to sustain the physiological healing
process." said Dr. Giorgio Reiner, Chief Scientific Officer at APR.

About Nexodyn® AcidOxidizing Solution (AOS)

Nexodyn® AcidOxidizing Solution (AOS) is the Tehclo-based cleanser
proven to restart wound healing in stalled wounds, by creating the
ideal microenvironment to sustain the physiological healing process.

A wealth of evidence and real-world experience consistently show
accelerated closure with reduced infection rates and less
wound-associated pain.

Developed based on APR's proprietary and patented technology
Tehclo®, Nexodyn® AOS is a newly conceived solution with three main
features: highly pure and stabilized hypochlorous acid (HClO >95% of
free chlorine species), acidic pH (2.5 - 3.0) and high
Reduction-Oxidation Potential (ORP 1.000 - 1.200 mV).

The product is a sprayable solution with ancillary antimicrobial
properties intended for use in the debridement, irrigation, cleansing
and moistening of acute and chronic wounds (e.g. diabetic foot
ulcers, pressure ulcers, and vascular ulcers), post-surgical wounds,
burns and other lesions.

For more info, please visit: http://www.apr.ch/apr-pharma-products
/medical-prescription/nexodyn-wound-healing/

About APR Applied Pharma Research s.a.

APR is a Swiss independent pharma company focused on development
and global commercialization of innovative, research-driven products
designed to address unmet needs in specialized therapeutic areas and
rare diseases. APR combine pharmaceutical development expertise with
proprietary drug delivery technologies to realize solutions that
meaningfully improve the lives of people with rare diseases and
empower families through novel approaches to disease management. A
diverse and balanced portfolio of revenue-generating products in all
major markets is complemented by a robust pipeline of innovative
products at different stages of development for the treatment of
recessive metabolic disorders, as well as rare dermatological and
ocular diseases. Products are directly commercialized by APR through
inhouse sales and marketing teams in strategically important
countries across Europe and a growing worldwide network of commercial
partners. For more information about the company, please visit the
website: www.apr.ch.

Contacts:

Elisabetta Bianchi
Corporate Communication Manager
elisabetta.bianchi@apr.ch
+41-91-6957020

ots Originaltext: APR Applied Pharma Research s.a.
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: APR Applied Pharma Research s.a., übermittelt durch news aktuell